Table 2 Univariate analysis for the overall survival and 5-year leukemia-free survival in MDS patients

From: Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome

Variable	No. of patients	Median OS ± SE, month	P-value	No. of patients	5-year LFS (%)	P-value
Age			0.001			0.556
≧65 years	221	26.3 ± 3.6		199	68.1 ± 6.1
<65 years	205	39.7 ± 16.5		181	60.4 ± 5.2
Gender			0.014			0.173
Male	281	26.3 ± 3.1		252	59.1 ± 5.1
Female	145	41.6 ± 16.9		128	71.7 ± 5.8
IPSS			<0.001			<0.001
Low/Int1	249	69.9 ± 12.4		249	73.5 ± 4
Int2/high	177	10.5 ± 1.1		131	38.7 ± 10.4
IPSS-R			<0.001			<0.001
Very low/low	118	83.6 ± 15.2		118	88.2 ± 4.1
Intermediate	108	47.2 ± 14.6		106	60.8 ± 7.1
High	106	17.7 ± 1.2		86	52.6 ± 7.8
Very high	94	7.8 ± 0.6		70	29.6 ± 14.1
Mutations
NRAS			0.114			0.001
Mutated	19	31.9 ± 2.6		11	31.8 ± 17.5
Wild type	407	15.9 ± 3.6		369	66.3 ± 4.1
KRAS			0.524			0.302
Mutated	6	17.7 ± 4.6		5	53.3 ± 24.8
Wild type	420	31.1 ± 2.8		375	65.5 ± 3.7
CBL			0.001			0.009
Mutated	13	11.8 ± 2.1		12	38.6 ± 17.3
Wild type	413	32.5 ± 2.7		368	66.1 ± 3.8
FLT3/ITD			0.289			0.003
Mutated	5	16.9 ± 5.7		4	25.0 ± 21.7
Wild type	421	31.3 ± 2.6		376	65.6 ± 3.8
JAK2			0.989			0.396
Mutated	4	19 ± 7.0		3	100
Wild type	422	30.9 ± 2.8		373	64.9 ± 3.7
RUNX1			0.008			<0.001
Mutated	52	18.6 ± 4.0			34.6 ± 10.4
Wild type	374	32.5 ± 2.4			68.8 ± 3.9
GATA2			0.150			0.903
Mutated	11	NA		9	65.6 ± 20.9
Wild type	415	30.9 ± 2.8		371	65.1 ± 3.8
IDH1			0.285			0.402
Mutated	4	15 ± 3.5		2	0
Wild type	422	31.9 ± 2.5		378	65.4 ± 3.7
IDH2			0.02			0.081
Mutated	18	18.5 ± 6.6		13	56 ± 17.1
Wild type	408	32.6 ± 2.5		367	65.9 ± 3.8
DNMT3A			0.035			0.137
Mutated	42	16.9 ± 3.9		37	33 ± 23.8
Wild type	384	32.7 ± 2.8		343	65.3 ± 4.0
TET2			0.022			0.305
Mutated	59	20.1 ± 3.2		57	60.2 ± 10.1
Wild type	367	31.9 ± 2.9		323	65.8 ± 4.0
ASXL1			<0.001			<0.001
Mutated	96	18.7 ± 2.6		84	30.8 ± 9.7
Wild type	330	36.3 ± 8.1		296	73.2 ± 3.8
EZH2			0.044			<0.001
Mutated	27	17 ± 2.2		25	36.4 ± 14.1
Wild type	399	32.5 ± 2.7		355	67.1 ± 3.8
MLL/PTD			0.149			0.018
Mutated	5	16.9 ± 0.6		3	0
Wild type	421	31.1 ± 2.8		377	66.7 ± 3.8
U2AF1			0.316			0.1
Mutated	31	31.3 ± 4.9		27	13.9 ± 12.4
Wild type	395	30.9 ± 3.1		353	69.5 ± 3.4
SRSF2			0.001			0.014
Mutated	58	18.5 ± 3.7		52	24.6 ± 18.5
Wild type	368	33.8 ± 3.3		328	68.3 ± 3.8
SF3B1			0.482			0.645
Mutated	47	39.7 ± 11.3		43	70.6 ± 9.8
Wild type	379	29.3 ± 3.1		337	64.4 ± 4
ZRSR2			0.008			0.525
Mutated	41	14 ± 2.1		37	63.7 ± 11
Wild type	385	32.7 ± 2.9		343	65.2 ± 3.9
SETBP1			0.988			0.163
Mutated	14	36.4 ± 16.8		13	45.5 ± 16.6
Wild type	412	31.1 ± 2.7		367	65.7 ± 3.8
TP53			<0.001			<0.001
Mutated	41	6.6 ± 1.2		29	41.3 ± 11.9
Wild type	285	36.1 ± 3.0		351	67.2 ± 3.8
Cohesin ^a			0.005			<0.001
Mutated	31	22.5 ± 4.3		23	21.5 ± 12.2
Wild type	395	33.8 ± 3.4		357	68.1 ± 3.8

OS overall survival, CI confidence interval, IPSS international prognostic scoring system, IPSS-R revised IPSS, LFS leukemia-free survival
^aCohesin genes, including RAD21, STAG1, STAG2, SMC1A, and SMC3

Back to article page

Table 2 Univariate analysis for the overall survival and 5-year leukemia-free survival in MDS patients

Search

Quick links